CN109260325A - A kind of point-application ointment and preparation method thereof - Google Patents
A kind of point-application ointment and preparation method thereof Download PDFInfo
- Publication number
- CN109260325A CN109260325A CN201810979546.4A CN201810979546A CN109260325A CN 109260325 A CN109260325 A CN 109260325A CN 201810979546 A CN201810979546 A CN 201810979546A CN 109260325 A CN109260325 A CN 109260325A
- Authority
- CN
- China
- Prior art keywords
- ointment
- chinese medicine
- parts
- point
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims description 15
- 239000003814 drug Substances 0.000 claims abstract description 77
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940070384 ventolin Drugs 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000001954 sterilising effect Effects 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 12
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241001078983 Tetradium ruticarpum Species 0.000 claims abstract description 12
- 229940116229 borneol Drugs 0.000 claims abstract description 12
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 12
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 229910000831 Steel Inorganic materials 0.000 claims 1
- 239000010959 steel Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 210000003240 portal vein Anatomy 0.000 abstract description 9
- 230000000840 anti-viral effect Effects 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 3
- 208000002672 hepatitis B Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 238000001467 acupuncture Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 238000010579 first pass effect Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000009724 venous congestion Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of point-application ointment, Chinese medicine are 5 parts of radix tetrastigme, 2 parts of Radix Salviae Miltiorrhizae, 2 parts of evodia rutaecarpa and 1 part of borneol in mass ratio；The ratio of Chinese medicine and medical ventolin ointment is 100g:100ml.Chinese medicine is ground into the smalls of 80 mesh；Medical ventolin ointment is measured according to the ratio of 100g Chinese medicine ratio 100ml medical ventolin ointment, medical ventolin ointment is put into after water proof molten is at paste in 100 degree of boiled water, Chinese medicine is added, stirs evenly, then carries out autoclave sterilization in pressure cooker, help and release 20 minutes；Stand 24 hours obtained ointment.Drug composition has clearing heat and detoxicating (antiviral), the effect of nourishing blood and liver (improving liver portal vein extravasated blood state), when not using any antiviral treatment, the art of this patent is used alone and sticks, has and inhibit HBVDNA duplication, improve portal venous flow speed effect.
Description
Technical field
The invention belongs to drug preparation technique field, in particular to a kind of point-application ointment and preparation method thereof.
Background technique
Chronic HBV infection includes chronic hepatitis B, hepatitis b cirrhosis, carrier and invisible chronic type b liver
It is scorching.Chronic hepatitis B (slow hepatitis B), belongs to chronic refractory infectious disease.China is the high Endemic Area of slow hepatitis B, hepatitis B prevention and treatment
Have become great one of the public health problem in China.Inhibiting HBV-DNA duplication is the critical issue of HBV infection treatment, though
So, antiviral drugs used at present can effective suppressing virus replication, still, since there are Long-term taking medicine, drug resistance and livers
First pass effect clinical problem, but become antiviral treatment puzzlement doctors and patients' in terms of curative compliance and medical treatment cost
Particular problem.It researches and develops effective to slow hepatitis B treatment or promotes the Chinese traditional treatment technology and mechanism study of curative effect, there is medical research
Necessity.And the development trend and the problem in science to be solved of traditional Chinese medicine research.
Slow hepatitis B is subordinate to the diseases scopes such as traditional Chinese medicine jaundice, hypochondriac pain, bulging, ruffian disease, consumptive disease, and the interpretation of the cause, onset and process of an illness is in Shi Re Bing Pian
It invades, checks do not remove long, weakened body resistance anti-heresy cannot long for disease.Initial stage based on the domination of pathogen, prolonged illness then deficiency of vital energy and blood, deficiency of liver-blood, so that liver is not
It must support, liver catharsis is not normal, mechanism of qi is checked, so that qi depression to blood stasis, extravasated blood resistance network etc..It treats with strengthening vital QI to eliminate pathogenic factors, dispersing liver and promoting blood circulation and is
The main rules for the treatment of.It is outstanding in terms of protecting liver, lowering enzymes, improving immunity of organism, anti-hepatic fibrosis, improving clinical symptoms, life is turned up
It is beneficial.
In recent years, domestic scholars take acusector, point-application, acupoint injection therapy etc. and carry out intervening grinding for slow hepatitis B treatment
Study carefully, Research Literature proves, the curative effect that needle pierces joint conventional therapy cirrhosis is better than only with conventional therapy, and improves treatment
The features such as there is compliance curative effect to stablize, and adverse reaction is few.Point medicine utilizes medicine irritation acupuncture point, and excitation body itself is exempted from
The regulatory function of epidemic disease can achieve the purpose for the treatment of both manifestation and root cause of disease.
Chinese medicine application therapy is the feature therapies of Chinese medicine, and Qing Dynasty's Wu Shi machine proposes that " reason controlled outside is i.e. in " reason fall the parallel prose "
The reason inside controlled, the medicine controlled outside that is, the interior medicine controlled.The different person of institute, method ear ".Currently, Chinese medicine application has been widely used in clinic
In each section.Studies have shown that Chinese medicine application has storage effect in keratoderma, plasma concentration curve can be made to tend towards stability, it is excellent
In other administration modes, and without stomach and gastral first-pass effect, the bioavilability of drug is greatly improved.This reduction body
Interior drug metabolism burden, avoids the treatment technology of blood born chance, meets HBV infected patient treatment hope and clinical application
Demand.
Existing acupoint application treatment studies have shown that slow hepatitis B patient through Chinese medicine application therapy treatment after its symptom and body
Sign has a degree of improvement, is obviously improved wherein receiving the symptoms such as poor, burnout, abdominal distension, uncomfortable liver area.Domestic scholars
It proposes, the mechanism of action of application treatment slow hepatitis B are as follows: directly improvement Microcirculation of Liver accelerates liver metabolism, it is scorching to mitigate liver cell
Property necrosis.Its applied Chinese medicine has the function of antiviral, centralizing qi, is removing patient's body HBV, is improving immunity of organism
Also there is remarkable result in terms of power.
There are problems for acupoint therapy: 1. acupuncture point selection is lack of standardization, and same disease selects Different Acupoint or selects cave too many；2. slow
It is mostly to lack the adjunct acupuncture points method by human trial verifying science mechanism according to theoretical acupoint selection that hepatitis B, which sticks adjunct acupuncture points,；3. needle thorn and
There are the risks of hospital-acquired infection for point medicine；4. the effect of slow hepatitis B point-application medication lacks to be separately applied and sees tides and demonstrate,prove
Bright effective research.5. the preparation method of point-application medication is to use after being reconciled using solvent, there are effective ingredients
Discharge drawback insufficient, not easy to maintain.
Summary of the invention
The object of the present invention is to provide a kind of point-application ointment and preparation method thereof, can be used for the chronic liver diseases such as slow hepatitis B
Patient's detoxification and removing stasis, nourishing blood and liver.
The technical solution of use:
A kind of point-application ointment, is mainly formulated by Chinese medicine and medical ventolin ointment, it is characterised in that:
Chinese medicine is 5 parts of radix tetrastigme, 2 parts of Radix Salviae Miltiorrhizae, 2 parts of evodia rutaecarpa and 1 part of borneol in mass ratio；
Wherein, the ratio of Chinese medicine and medical ventolin ointment is 100g:100ml.
A kind of preparation method of point-application ointment, it is characterised in that: include the following steps,
Step 1: being in mass ratio 5 parts of radix tetrastigme, 2 parts of Radix Salviae Miltiorrhizae, 2 parts of evodia rutaecarpa and 1 part of borneol weigh Chinese medicine, by Chinese medicine
It is ground into the smalls of 80 mesh.
Step 2: medical ventolin ointment is measured according to the ratio of 100g Chinese medicine ratio 100ml medical ventolin ointment, is placed in
In stainless steel ware, vessel are put into after water proof molten is at paste in 100 degree of boiled water, Chinese medicine is added, stirs evenly, then 98~
The pressure of 147kPa carries out autoclave sterilization 20 minutes in 115 DEG C~123 DEG C of high-pressure steam sterilizing pan.
Step 3: 24 hours obtained ointment are stood under 22~25 DEG C of environment.Drug is placed in closed container, 15~
It is saved in 25 DEG C of environment.
Preferably, the closed container in above-mentioned steps three is port grinding bottle.
Radix tetrastigme: nature and flavor: slight bitter is put down.Function: clearing heat and detoxicating, dispelling pathogenic wind and eliminating phlegm, promoting blood circulation and stopping pain are monarch drug in a prescription.
Radix Salviae Miltiorrhizae: nature and flavor: bitter, it is slightly cold, return the few yin of brothers, meridian of Foot-JUE YIN.Major function: stasis-dispelling and pain-killing, blood circulation, clearly
Heart relieving restlessness.
Borneol: nature and flavor are pungent, bitter, slightly cold.Return heart, spleen, lung channel.Major function: inducing resuscitation of having one's ideas straightened out, clearing away heat to and alleviating pain.
Help radix tetrastigme clearing heat and detoxicating for adjutant
Evodia rutaecarpa: nature and flavor are pungent, bitter, heat；It is slightly poisonous.Return liver, spleen, stomach, kidney channel.Major function: check, drops in eliminating cold to stop pain
It vomits, supporing yang antidiarrheal takes it to enter the leading action of Liver Channel.
A kind of point-application method for chronic liver disease, it is characterised in that:
Step 1: become using by HBV infection patient through cave body surface infrared temperature and clinical diagnosis correlation, infrared temperature
Change and studied with liver portal vein Hemodynamics dependence on parameter, there are specific findings, and meets traditional Chinese medicine in relation to " Yu, which raises, to be matched
The infrared-sensitive of cave " and " treating blood trouble in yin channel Qie cave " acupuncture theory is through cave.
Stick acupuncture point: liver is raised Qimen, the back shu points kan shu of liver, in Liver Channel Qie cave all.
Qimen (LR14): in chest, 4 cun (Fig. 1) are opened by anterior median line in the 6th intercostal space；
Kan shu (BL18): 1.5 cun (Fig. 2) are opened under spinal area, the 9th spinous process of thoracic vertebra, by posterior median line；
In all (LR6): in medial leg, upper 7 cun of internal malleolus point, facies medialis tibiae center (Fig. 3).
Step 2: it after 75% cotton ball soaked in alcohol routine disinfection of acupuncture point, takes 2-3 grams of ointment to be applied to stick and stick, then sticks
In on acupuncture point, is voluntarily taken down after 6 hours and stick drug paste.Every application treatment on the 3rd is primary.30 times as a treatment course.
Indication: this applying method has detoxification and removing stasis, the effect of nourishing blood and liver.It can be used as chronic hepatitis B patient suppression
HBVDNA processed replicates, improves the supplement substitute technology application of portal vein extravasated blood.
Target user: chronic hepatitis B, chronic hepatitis B cirrhosis, and need the various Chronic Livers of nourishing blood and liver
The adjuvant treatment of disease.
Technological invention point is embodied in:
1. sticking the infrared-sensitive for deriving from slow hepatitis B patient human experimentation research with cave prescription through cave, there is scientific basis
And meet traditional Chinese medicine correlation theory.Prescription cave is simple, stablizes.It is nonstandard to solve current similar treatment method cave method
Problem.
2. it is motivated to stick medication.Inhibiting HBV-DNA duplication is the critical issue of HBV infection treatment, still, for a long time
Medication antiviral drugs, there are the clinical problems of drug resistance and the first pass effect of liver；Improve Microcirculation of Liver, accelerates liver generation
It thanks, mitigates liver cell inflammatory necrosis, there is the significance of prevention liver fibrosis.This patent collection is antiviral and improves portal vein silt
Blood acts on the new point-application medicine composition being integrated.As supplement alternative medicine, external treatment with Chinese medicine technology is innovated and has seen virus
New method.
3. this patent helps the method for releasing using point-application ointment high temperature and pressure, utmostly improves effective ingredient and release
It puts and Transdermal absorption, has innovated the preparation method of point-application drug.
The advantage is that: this patent is by summarizing Liaoning Department of Education of Shanxi Province scientific and technical research project, Shenyang City's science and technology meter
Project, Liaoning Province's nature fund project are drawn, 7 years research achievements are lasted, in chronic HBV infection patient infrared-sensitive through real on cave
Apply the technical solution of Chinese medicine application treatment.Treatment cave science, and meet acupuncture theory and science of the traditional Chinese medicine in relation to specific acupoint
The biomedicine basis of research；Drug composition has clearing heat and detoxicating (antiviral), nourishing blood and liver (improvement liver portal vein extravasated blood shape
State) effect, also, pass through HBV infection patient, HBVDNA carrying capacity > 102/, human trial show do not use it is any disease-resistant
Under cytotoxic drug treatment condition, the art of this patent is used alone and sticks, has and inhibit HBVDNA duplication, improve portal venous flow speed
Effect.
Inhibiting HBV-DNA duplication is the critical issue of HBV infection treatment, and still, Long-term taking medicine antiviral drugs, there are resistance to
The clinical problem of the first pass effect of pharmacological property and liver；Improve Microcirculation of Liver, accelerate liver metabolism, it is bad to mitigate liver cell inflammatory
Extremely, there is the significance of prevention liver fibrosis.This patent integrates antiviral and improves the effect of portal vein extravasated blood.As benefit
Alternative medicine is filled, there is application value and meaning.
This patent use sticks ointment high temperature and helps the method for releasing, and utmostly improves effective ingredient release and transdermal suction
It receives, has innovated the application method of point-application.
Detailed description of the invention
Fig. 1 Qimen sticks acupuncture point schematic diagram.
Fig. 2 kan shu sticks acupuncture point schematic diagram.
In Fig. 3 all stick acupuncture point schematic diagram.
The pretherapy and post-treatment HBVDNA of Fig. 4 replicates carrying capacity mean value statistical chart.
Fig. 5 virus replication carrying capacity trend chart.
Fig. 6 treats effective crowd's Virus State analysis chart.
Fig. 7 is VPV statistical results chart.
Fig. 8 is DPV statistical results chart.
Fig. 9 is CI statistical results chart.
Specific embodiment
Embodiment 1
A kind of point-application ointment, is mainly formulated by Chinese medicine and medical ventolin ointment, it is characterised in that:
Chinese medicine is radix tetrastigme 50g, Radix Salviae Miltiorrhizae 20g, evodia rutaecarpa 20g and borneol 10g by quality；Wherein, medical ventolin ointment
For 100ml.
Embodiment 2
A kind of preparation method of point-application ointment, it is characterised in that: include the following steps,
Step 1: being that radix tetrastigme 50g, Radix Salviae Miltiorrhizae 20g, evodia rutaecarpa 20g and borneol 10g weigh Chinese medicine by quality, by traditional Chinese medicine powder
It is broken into the smalls of 80 mesh.
Step 2: medical ventolin ointment 100ml is measured, is placed in stainless steel ware, vessel is put into 100 degree of boiled water
After water proof molten is at paste, be added Chinese medicine, stir evenly, then in the pressure of 147kPa, 123 DEG C of high-pressure steam sterilizing pan into
Row autoclave sterilization is helped and is released 20 minutes.
Step 3: 24 hours obtained ointment are stood under 22-25 DEG C of environment.Drug is placed in port grinding bottle.At 15-25 DEG C
It is saved in environment.
Embodiment 3:
A kind of preparation method of point-application ointment, it is characterised in that: include the following steps,
Step 1: being that radix tetrastigme 50g, Radix Salviae Miltiorrhizae 20g, evodia rutaecarpa 20g and borneol 10g weigh Chinese medicine by quality, by traditional Chinese medicine powder
It is broken into the smalls of 80 mesh.
Step 2: medical ventolin ointment 100ml is measured, is placed in stainless steel ware, vessel is put into 100 degree of boiled water
After water proof molten is at paste, be added Chinese medicine, stir evenly, then in the pressure of 125kPa, 115 DEG C of high-pressure steam sterilizing pan into
Row autoclave sterilization is helped and is released 20 minutes.
Step 3: 24 hours obtained ointment are stood under 22-25 DEG C of environment.Drug is placed in glass port grinding bottle in 15-25
It is saved in DEG C environment.
Embodiment 4
A kind of preparation method of point-application ointment, it is characterised in that: include the following steps,
Step 1: being that radix tetrastigme 50g, Radix Salviae Miltiorrhizae 20g, evodia rutaecarpa 20g and borneol 10g weigh Chinese medicine by quality, by traditional Chinese medicine powder
It is broken into the smalls of 80 mesh.
Step 2: medical ventolin ointment 100ml is measured, is placed in stainless steel ware, vessel is put into 100 degree of boiled water
After water proof molten is at paste, be added Chinese medicine, stir evenly, then in the pressure of 147kPa, 115 DEG C of high-pressure steam sterilizing pan into
Row autoclave sterilization is helped and is released 20 minutes.
Step 3: 24 hours obtained ointment are stood under 22-25 DEG C of environment.Drug is placed in glass port grinding bottle in 15-25
It is saved in DEG C environment.
Embodiment 5:
A kind of preparation method of point-application ointment, it is characterised in that: include the following steps,
Step 1: being that radix tetrastigme 50g, Radix Salviae Miltiorrhizae 20g, evodia rutaecarpa 20g and borneol 10g weigh Chinese medicine by quality, by traditional Chinese medicine powder
It is broken into the smalls of 80 mesh.
Step 2: medical ventolin ointment 100ml is measured, sets in stainless steel ware, vessel is put into 100 degree of boiled water intervals
After water molten is at paste, Chinese medicine is added, stirs evenly, then carried out in the pressure of 125kPa, 123 DEG C of high-pressure steam sterilizing pan
Autoclave sterilization is helped and is released 20 minutes.
Step 3: 24 hours obtained ointment are stood under 22-25 DEG C of environment.Drug is placed in glass port grinding bottle in 15-25
It is saved in DEG C environment.
Embodiment 6
A kind of preparation method of point-application ointment, it is characterised in that: include the following steps,
Step 1: being that radix tetrastigme 50g, Radix Salviae Miltiorrhizae 20g, evodia rutaecarpa 20g and borneol 10g weigh Chinese medicine by quality, by traditional Chinese medicine powder
It is broken into the smalls of 80 mesh.
Step 2: medical ventolin ointment 100ml is measured, sets in stainless steel ware, vessel is put into 100 degree of boiled water intervals
After water molten is at paste, Chinese medicine is added, stirs evenly, then carried out in the pressure of 98kPa, 115 DEG C of high-pressure steam sterilizing pan
Autoclave sterilization is helped and is released 20 minutes.
Step 3: 24 hours obtained ointment are stood under 22-25 DEG C of environment.Drug is placed in glass port grinding bottle in 15-25
It is saved in DEG C environment.
Implementation achievement
Detoxification and liver protection note inhibits the clinical observation of HBVDNA print effect
Research object and method: HBV infection patient, HBVDNA duplication amount are greater than 1 × 102Copy/ml is not implemented any anti-
Viral drug treatment measure.Observation group 30, using this method application treatment 10 times (three weeks), blank control group is no any to arrange
It applies.Treatment results are as follows:
(1) the pretherapy and post-treatment virus replication measurer of application treatment group has larger difference (P < 0.05), before blank control group treatment
No significant difference (P > 0.05) (Fig. 4) between afterwards.
(2) the case load institute accounting reduced before and after treatment compared to virus replication amount (with clinical efficacy) in treatment group is
74%, wherein being 44% in case load institute's accounting of power decline (curative effect has clinical meaning), control group accounting is 11%.
(3) with hepatitis B in " the guideline " [2] again activity standard (hbv replication amount be greater than 1 ×
105Copy/ml) be grouped, as the result is shown in treatment group initial HBV-DNA carrying capacity be in low-level patient's curative effect compared with
It is good.
Detoxification and liver protection note improves the effect clinical observation of portal vein extravasated blood
Research object and method: the same.
Result of study:
(1) the pretherapy and post-treatment mean value paired-samples T-test of VPV statistical result (Fig. 7), treatment group and control group are VPV1 >
VPV2, P > 0.05；Mean value Mann-Whitney is examined between group, VPV1 treatment group > control group, P > 0.05, VPV2 treatment group
> control group, P < 0.05.It prompts point-application to have and promotes portal venous flow speed, improve the meaning of portal vein extravasated blood state.
The pretherapy and post-treatment mean value paired-samples T-test of 2.3DPV statistical result (Fig. 8), treatment group DPV1 > DPV2, P > 0.05；It is right
According to group DPV1 < DPV2, P a > 0.05.Pair test is treatment group's > control group, P < 0.05 between DPV1 and DPV2 group.Prompt
Portal vein diameter has the tendency that becoming smaller after acupoint therapy.
The pretherapy and post-treatment mean value paired-samples T-test of 2.4CI statistical result (Fig. 9), treatment group CI1 > CI, P > 0.05, control group
CI1 < CI2, P > 0.05.Pair test is treatment group's > control group, P > 0.05 between CI1 and CI2 group.Acupoint therapy, which has, to be changed
The trend of charitable family's venous congestion state.
Claims (3)
1. a kind of point-application ointment, is mainly formulated by Chinese medicine and medical ventolin ointment, it is characterised in that:
Chinese medicine is 5 parts of radix tetrastigme, 2 parts of Radix Salviae Miltiorrhizae, 2 parts of evodia rutaecarpa and 1 part of borneol in mass ratio；
Wherein, the ratio of Chinese medicine and medical ventolin ointment is 100g:100ml.
2. a kind of preparation method of point-application ointment, it is characterised in that: include the following steps,
Step 1: being in mass ratio 5 parts of radix tetrastigme, 2 parts of Radix Salviae Miltiorrhizae, 2 parts of evodia rutaecarpa and 1 part of borneol weigh Chinese medicine, and Chinese medicine is crushed
At the smalls of 80 mesh；
Step 2: medical ventolin ointment is measured according to the ratio of 100g Chinese medicine ratio 100ml medical ventolin ointment, is placed in stainless
In steel ware, vessel are put into after water proof molten is at paste in 100 degree of boiled water, Chinese medicine is added, stirs evenly, then 98~
The pressure of 147kPa carries out autoclave sterilization 20 minutes in 115 DEG C~123 DEG C of high-pressure steam sterilizing pan；
Step 3: 24 hours obtained ointment are stood under 22~25 DEG C of environment；Drug is placed in closed container, at 15~25 DEG C
It is saved in environment.
3. a kind of preparation method of point-application ointment according to claim 2, it is characterised in that: in above-mentioned steps three
Closed container is port grinding bottle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810979546.4A CN109260325A (en) | 2018-08-27 | 2018-08-27 | A kind of point-application ointment and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810979546.4A CN109260325A (en) | 2018-08-27 | 2018-08-27 | A kind of point-application ointment and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109260325A true CN109260325A (en) | 2019-01-25 |
Family
ID=65154494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810979546.4A Pending CN109260325A (en) | 2018-08-27 | 2018-08-27 | A kind of point-application ointment and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109260325A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111840430A (en) * | 2020-06-05 | 2020-10-30 | 浙江农林大学 | Radix tetrastigme patch with quick-acting pain relieving function and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660282A (en) * | 2004-12-09 | 2005-08-31 | 杨雄志 | Combination of medication for treating hepatitis B and preparation method |
| CN1814250A (en) * | 2005-12-05 | 2006-08-09 | 杨雄志 | Chinese medicine composition for treating liver cirrhosis ascites and use thereof |
| CN1899574A (en) * | 2006-06-30 | 2007-01-24 | 杨熠锴 | Chinese medicine composition for preventing and controlling liver cancer and its use |
-
2018
- 2018-08-27 CN CN201810979546.4A patent/CN109260325A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660282A (en) * | 2004-12-09 | 2005-08-31 | 杨雄志 | Combination of medication for treating hepatitis B and preparation method |
| CN1814250A (en) * | 2005-12-05 | 2006-08-09 | 杨雄志 | Chinese medicine composition for treating liver cirrhosis ascites and use thereof |
| CN1899574A (en) * | 2006-06-30 | 2007-01-24 | 杨熠锴 | Chinese medicine composition for preventing and controlling liver cancer and its use |
Non-Patent Citations (1)
| Title |
|---|
| 周歆等: "HBV 感染者红外敏感经穴贴敷对病毒载量影响的临床探索", 《辽宁中医杂志》, vol. 44, no. 2, pages 322 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111840430A (en) * | 2020-06-05 | 2020-10-30 | 浙江农林大学 | Radix tetrastigme patch with quick-acting pain relieving function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102085319A (en) | Medicament for treating verruca plana and preparation method thereof | |
| CN104383055A (en) | Drug for treating end-stage liver diseases caused by chronic hepatitis B and preparation method of drug | |
| CN102357177B (en) | Traditional Chinese medicine for curing climacteric metancholia | |
| CN103463494B (en) | One treats hypertensive Chinese medicine preparation | |
| CN109260325A (en) | A kind of point-application ointment and preparation method thereof | |
| CN101112533B (en) | A Chinese medicinal composition for treating and preventing gout, and its preparation method | |
| CN104906388A (en) | Dendrobium officinale traditional Chinese medicine recuperating tea for preventing sub-health | |
| CN102716334B (en) | Chinese medicinal composition for dispelling the cold and removing stasis | |
| CN101810826B (en) | Chinese medicament for treating liver cancer | |
| CN104940418A (en) | Pure traditional Chinese medicine pills for treating hepatitis and preparation method thereof | |
| CN1404867A (en) | Chinese medicine for treating hyperplasia of mammary glands | |
| CN103142707A (en) | Traditional Chinese medicine paste or treating chronic soft tissue injury and preparation method thereof | |
| CN101085165A (en) | Internal-applied traditional Chinese medicine composition for treating viral myocarditis | |
| Xu et al. | Clinical observation on tuina plus foot bath with Chinese medicine for diabetic foot in early stage | |
| CN102872416A (en) | Traditional Chinese medicine sitting lotion for treating chronic prostatitis | |
| CN104689288B (en) | A kind of Chinese medicine preparation for treating chronic hypotension | |
| CN102406837A (en) | Traditional Chinese preparation for treating atrophic debilitys | |
| CN103054979A (en) | Traditional Chinese medical formula for treating neonatal jaundice | |
| CN107693621A (en) | Chinese medicine and its preparation for coronary heart disease myocardial infarction treatment | |
| CN101015671B (en) | Chinese patent drug for treating cirrhosis | |
| CN105687511A (en) | Traditional Chinese medicine composition for treating rheumatalgia and hand and foot numbness and preparation method thereof | |
| Li | Observations on the Therapeutic Effect of Point-Through-Point Acupuncture Plus Chinese Herbal Medicine on Intractable Hiccup in Tumor Patients. | |
| CN102335389B (en) | Kidney-tonifying spleen-nourishing traditional Chinese medicine formula for treating chronic hepatitis B and chronic hepatitis B virus carriers | |
| CN104367652A (en) | Traditional Chinese medicine composition for treating sub-health and preparation method thereof | |
| CN103463375A (en) | Traditional Chinese medicine composition for treating chronic type viral hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190125 |